13F Holdings
中文EN

SVA SINOVAC BIOTECH LTD Annual reports only

Pharmaceutical Preparations · Nasdaq · SEC CIK 1084201 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY6.8%
TTM net income YoY-165.7%
TTM EPS YoY-165.4%
Revenue 3-yr CAGR-36.0%
Net income 3-yr CAGR—

Margins

Gross margin67.9%
Operating margin-127.0%
Net margin-15.5%
FCF margin-145.4%
EBITDA margin-101.7%

Returns

ROE-0.9%
ROA-0.6%
ROIC (approx.)-6.1%
Asset turnover0.04x

Leverage & solvency

Liabilities / assets25.1%
Debt / equity0.11x
Current ratio4.59x
Interest coverage-49.92x

Cash quality & payout

Operating cash flow / net income8.58x
Accruals ratio4.3%
Payout ratio—
Capex / revenue12.7%

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Line item FY2025*2025-12-31FY2024*2024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$386.01M$361.37M$470.17M$1.47B$19.37B
Cost of revenue$124.03M$140.69M$146.85M$658.19M$988.92M
Gross profit$261.98M$220.69M$323.32M$815.24M$18.38B
R&D expense$216.18M$270.66M$350.19M$478.69M$152.70M
SG&A expense$332.98M$420.92M$598.25M$836.14M$602.15M
Operating income-$490.13M-$505.54M-$713.98M-$508.99M$17.62B
Interest expense$9.82M$5.64M$4.94M$1.26M$2.84M
Pretax income-$262.10M$42.84M-$84.49M-$48.48M$17.57B
Income tax-$63.27M$2.18M$36.37M$11.48M$3.45B
Net income-$59.68M$90.91M-$13.49M$14.47M$8.12B
EBITDA-$392.68M-$395.31M-$556.54M-$356.28M$17.70B
EPS (basic)-0.831.27-0.190.20113.54
EPS (diluted)-0.831.27-0.190.20113.44
Dividends declared per share55.00————
Weighted avg. shares (diluted)71.86M71.86M71.85M71.76M71.60M
Balance sheet
Cash & equivalents$488.25M$335.27M$1.13B$3.89B$11.61B
Short-term investments$5.48B$9.61B$9.89B$6.65B$1.81B
Receivables$286.34M$300.89M$424.94M$486.59M$942.74M
Inventory$94.31M$96.92M$135.61M$175.29M$391.07M
Current assets$7.06B$10.64B$11.60B$11.30B$14.94B
PP&E, net$706.06M$880.97M$951.98M$989.73M$855.03M
Goodwill$12.60M$27.51M$0$0$0
Intangibles$77.68M$122.58M$8.52M$9.70M$1.48M
Total assets$8.54B$12.34B$13.61B$14.03B$16.76B
Current liabilities$1.54B$1.45B$1.29B$1.26B$2.52B
Long-term debt$494.86M$375.76M$253.91M$11.81M$15.77M
Total debt$494.86M$375.76M$253.91M$11.81M$15.77M
Total liabilities$2.15B$2.04B$1.97B$1.79B$3.21B
Shareholders' equity$4.44B$8.26B$8.32B$8.49B$9.00B
Net debt$6.61M$40.49M-$875.22M-$3.88B-$11.59B
Shares outstanding71.86M71.86M71.86M71.72M71.72M
Cash flow statement
Operating cash flow-$512.18M-$56.89M$138.65M-$798.12M$15.32B
Capital expenditure$48.92M$95.96M$156.16M$313.86M$594.21M
Free cash flow-$561.10M-$152.85M-$17.52M-$1.11B$14.73B
Investing cash flow$4.39B$456.36M-$2.70B-$6.09B-$2.98B
Financing cash flow-$3.43B-$823.95M-$88.55M-$299.53M-$1.91B
Depreciation & amortization$97.45M$110.23M$157.45M$152.70M$85.07M
Stock-based compensation$0$0$0$0$7.74M
Dividends paid$3.53B$947.00M$328.08M$247.40M$1.88B

Free plan shows the latest 5 periods; Pro shows all 18 🔒

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.